United States Patent 8,685,984: Scope, Claims, Expiration, and HCV Patent Landscape
US Patent No. 8,685,984 covers interferon-free treatment of hepatitis C genotype 1 using combinations of direct-acting antivirals for eight to 12 weeks. The strongest commercial overlap is with the Harvoni regimen, consisting of sofosbuvir and ledipasvir, and with the former Viekira Pak regimen, consisting of ABT-450/ritonavir, ombitasvir, and dasabuvir. The patent is a method-of-treatment patent. It does not independently claim the chemical compounds, tablets, or manufacturing processes.
What does US Patent 8,685,984 cover?
The patent claims treatment of an HCV treatment-naive patient infected with genotype 1, without interferon or ribavirin, using specified DAA combinations for defined durations.
The claims divide into two principal regimen groups:
| Claim group |
Claimed regimen |
Duration |
Key dosing |
| Claims 1-5 and 12-16 |
Compound 1, Compound 2, and Compound 4, with ritonavir |
8-12 weeks |
Compound 1 150 mg QD, ritonavir 100 mg QD, Compound 4 25 mg QD, Compound 2 400 mg BID |
| Claims 6-11 and 17-20 |
PSI-7977 and GS-5885 |
8-12 weeks |
PSI-7977 400 mg QD and GS-5885 90 mg QD |
The claims also require, depending on the claim:
- Treatment-naive status.
- HCV genotype 1 infection.
- No interferon.
- No ribavirin.
- Administration of at least two DAAs.
- Eight weeks for claims 1-11.
- Eight, nine, 10, 11, or 12 weeks for claims 12-20.
- Genotype 1a for narrower dependent claims.
- Once-daily administration or co-formulation for selected dependent claims.
The supplied text for claim 1 omits the words following “said at least two DAAs comprise.” Claims 2 and 3 indicate that the intended combination is Compound 1, Compound 2, and Compound 4.
What are Compound 1, Compound 2, Compound 4, PSI-7977, and GS-5885?
The compound identifiers correspond to development-stage HCV antivirals used in the 2012-2014 development period.
| Patent identifier |
Commercial or development identity |
Pharmacologic class |
Relevant regimen |
| Compound 1 |
ABT-450, later paritaprevir |
NS3/4A protease inhibitor |
Administered with ritonavir |
| Compound 2 |
ABT-333, later dasabuvir |
Non-nucleoside NS5B inhibitor |
Twice-daily administration |
| Compound 4 |
ABT-267, later ombitasvir |
NS5A inhibitor |
Once-daily administration |
| PSI-7977 |
Sofosbuvir |
Nucleotide NS5B polymerase inhibitor |
400 mg once daily |
| GS-5885 |
Ledipasvir |
NS5A inhibitor |
90 mg once daily |
The first regimen corresponds to the core components of AbbVie’s Viekira Pak approach. The second corresponds to Gilead’s Harvoni combination. The compound mapping should be confirmed against the patent specification and prosecution record before use in litigation or a freedom-to-operate opinion.
How broad are the independent claims?
Claims 1, 6, and 12 are method claims with multiple limiting elements. Their apparent breadth is narrower than the phrase “at least two DAAs” suggests.
Claim 1
Claim 1 requires:
- An HCV treatment-naive patient.
- Genotype 1 infection.
- At least two DAAs.
- No interferon or ribavirin.
- An eight-week treatment period.
- The specified Compound 1, Compound 2, and Compound 4 combination, based on the dependent claims and the apparent claim omission.
- Ritonavir administration with Compound 1.
A treatment that uses only two of the three compounds would not necessarily fall within claim 1 if the complete claim requires all three compounds. The words “at least two” do not eliminate the additional requirement imposed by the specified combination.
Claim 6
Claim 6 is directed to PSI-7977 and GS-5885. It requires an eight-week, interferon-free and ribavirin-free regimen in a treatment-naive genotype 1 patient.
This claim has direct relevance to the 8-week Harvoni label for certain treatment-naive patients. The claim does not require a particular viral-load threshold, HIV status, fibrosis stage, or cirrhosis status on its face. Those limitations may appear elsewhere in the specification or FDA labeling but are not stated in the supplied claim.
Claim 12
Claim 12 expands the treatment period to eight through 12 weeks and covers either:
- Compound 1, Compound 2, and Compound 4; or
- PSI-7977 and GS-5885.
The use of “8, 9, 10, 11 or 12 weeks” is unusual but legally significant. A court would assess whether the listed periods define separate alternatives or create an ambiguity regarding continuous treatment duration. The dependent claims add regimen-specific dosing, co-formulation, administration frequency, and genotype 1a limitations.
Which products potentially practice the patent?
Harvoni
Harvoni combines sofosbuvir 400 mg and ledipasvir 90 mg in a once-daily fixed-dose tablet. The regimen directly corresponds to the PSI-7977 and GS-5885 language in claims 6-12 and 17-20.
The strongest overlap exists where treatment is:
- For a treatment-naive genotype 1 patient.
- Interferon-free.
- Ribavirin-free.
- Eight weeks in duration.
- Administered once daily.
- Provided as the fixed-dose sofosbuvir/ledipasvir tablet.
The claims do not require the two products to be administered in separate tablets. Claims 8 and 19 expressly address co-formulation.
Viekira Pak
Viekira Pak combined:
- Ombitasvir 25 mg once daily.
- Paritaprevir 150 mg once daily.
- Ritonavir 100 mg once daily.
- Dasabuvir 250 mg twice daily in the marketed product.
The claimed development dose for Compound 2 is 400 mg twice daily. That distinction matters. A marketed dose of 250 mg twice daily may not literally satisfy a claim requiring 400 mg twice daily, although the independent claims may still be relevant if they do not require the narrower dose.
The three-DAA combination in claims 1-5 and 12-16 corresponds closely to the Viekira Pak active ingredients. Viekira Pak was approved by the FDA in 2014 for genotype 1 infection, with treatment duration depending on genotype, cirrhosis, and prior treatment status [2].
Mavyret and other pangenotypic regimens
Mavyret contains glecaprevir and pibrentasvir. It does not contain the compounds identified in the patent claims. Epclusa contains sofosbuvir and velpatasvir, not GS-5885 or ledipasvir. These products generally do not fall within the literal scope of the supplied claims.
The patent is therefore not a general patent on all interferon-free DAA treatment. It is tied to named compound combinations and specific patient and duration limitations.
What FDA and Orange Book issues apply?
US Patent 8,685,984 is relevant to an FDA-approved combination containing sofosbuvir and ledipasvir if the patent is listed against the applicable New Drug Application. Orange Book relevance depends on the patent listing submitted by the NDA holder and the FDA’s published listing history, not solely on the patent’s claim language [3].
The key regulatory distinction is:
- Product patents cover the drug or formulation.
- Method-of-use patents cover an approved treatment use.
- Process patents cover manufacture.
- Orange Book-listed method patents can support a Paragraph IV notice where an ANDA applicant seeks approval for the patented use.
A generic applicant may avoid a method-of-use patent through a section viii statement if the patented use can be carved out from the proposed label. That strategy is more difficult where the patented regimen is central to the product’s approved indication or where the label cannot be meaningfully limited without affecting the proposed use.
When does US Patent 8,685,984 expire?
The patent has a 20-year term measured from the applicable nonprovisional US filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable statutory corrections. Based on the patent’s early-2010s filing history, its unadjusted expiration is expected to fall in the early 2030s, rather than at the 2024-2025 dates associated with several early HCV product patents.
The controlling expiration date is the USPTO Patent Center term calculation, including:
- Patent-term adjustment.
- Any terminal disclaimer.
- Continuation or divisional relationships.
- PTA attributed to USPTO examination delays.
- Any post-grant correction affecting term.
For commercial planning, the patent should be treated as potentially enforceable through approximately 2031 unless the official record establishes an earlier date.
What Paragraph IV and generic-entry risks exist?
The patent creates different risks for a generic sofosbuvir/ledipasvir product and for a generic version of the former Viekira Pak regimen.
Sofosbuvir/ledipasvir
A generic applicant seeking an indication that includes eight-week treatment for treatment-naive genotype 1 patients could face a Paragraph IV challenge if the patent is listed and the applicant alleges invalidity, noninfringement, or unenforceability.
The principal noninfringement arguments could involve:
- Patient population differences.
- A treatment duration outside the claimed period.
- A label limited to genotype 2, 3, 4, 5, or 6.
- Exclusion of treatment-naive patients.
- A label that does not recommend the patented combination.
- A section viii carve-out for the patented method.
The principal validity issues could involve:
- Anticipation by clinical-trial disclosures.
- Obviousness based on prior DAA combination studies.
- Written-description support for the specific treatment durations.
- Enablement of the claimed combinations and patient populations.
- Indefiniteness arising from compound identifiers or the omitted language in the supplied claim text.
Viekira-type products
The commercial risk is lower today because Viekira Pak is no longer a major US growth product. The patent remains relevant to historical damages, settlement analysis, and any later product using the same compound combination.
What patent litigation and settlement issues affect the patent?
The supplied record does not establish a final judicial ruling invalidating or narrowing US Patent 8,685,984. A complete litigation assessment must distinguish:
- Cases naming the patent directly.
- Cases involving related patents in the same family.
- Hatch-Waxman litigation involving Harvoni or Viekira Pak.
- Patent settlements that resolve commercial entry without a merits decision.
- Patent challenges involving different patents covering sofosbuvir, ledipasvir, paritaprevir, ombitasvir, or dasabuvir.
A settlement involving a related HCV patent does not automatically determine the enforceability or scope of US 8,685,984. Claim construction, prosecution history, and the specific notice letter remain decisive.
How strong is the patent estate?
The patent is strongest against a product or label that reproduces the complete claimed regimen. It is weaker against products that use different molecules, different treatment durations, or different patient populations.
| Risk factor |
Assessment |
| Direct overlap with 8-week sofosbuvir/ledipasvir therapy |
High |
| Direct overlap with 12-week sofosbuvir/ledipasvir therapy |
Potentially high under claim 12 |
| Coverage of all pangenotypic DAA therapy |
Low |
| Coverage of Mavyret |
Low |
| Coverage of the original Viekira regimen |
High if dose and other limitations are met |
| Manufacturing protection |
None apparent from the supplied claims |
| Composition-of-matter protection |
None from the supplied claims |
| Biosimilar exposure |
Not applicable |
| Generic litigation relevance |
Material if the patent is Orange Book-listed and the proposed label overlaps |
The main weakness is that the claims depend on a tightly defined clinical setting. A defendant may avoid infringement by changing the claimed molecule, patient population, duration, or label language. The main strength is the direct recitation of commercially recognizable combinations and marketed dosing schedules.
Does biosimilar law apply?
No. Sofosbuvir, ledipasvir, paritaprevir, ombitasvir, dasabuvir, and ritonavir are small-molecule drugs. Generic applicants use the Hatch-Waxman abbreviated new drug application pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.
The relevant challenges are Paragraph IV certifications, section viii statements, ANDA litigation, and possible authorized-generic or settlement arrangements.
What is the commercial exposure?
The principal historical exposure was Gilead’s Harvoni franchise and AbbVie’s Viekira franchise. Harvoni generated tens of billions of dollars in global sales during its peak commercial period, while Viekira generated materially lower revenue and was later displaced by newer pangenotypic treatments and AbbVie’s Mavyret [4][5].
The patent’s present economic value depends less on Viekira and more on:
- Remaining US term.
- Orange Book listing status.
- The scope of any generic Harvoni label.
- Validity of the 8- and 12-week method claims.
- Existing licenses or settlements.
- Whether the patent is enforceable against authorized generic entry.
Key Takeaways
- US 8,685,984 is a method-of-treatment patent, not a compound or manufacturing patent.
- The claims cover interferon-free, ribavirin-free treatment of treatment-naive genotype 1 HCV patients.
- The two central regimens are the sofosbuvir/ledipasvir combination and the paritaprevir/ritonavir/ombitasvir/dasabuvir combination.
- Claims 1-11 focus on eight-week treatment; claims 12-20 extend the claimed duration to eight through 12 weeks.
- The patent has direct potential relevance to Harvoni-style treatment and historical Viekira Pak treatment.
- Mavyret, Epclusa, and other products using different DAA combinations generally fall outside the literal claims supplied.
- Generic exposure depends on Orange Book listing, label overlap, section viii availability, and the patent’s effective expiration date.
- Biosimilar law does not apply.
- The expected patent term extends into the early 2030s, subject to the official USPTO term calculation.
FAQs
Can an eight-week Harvoni regimen infringe US Patent 8,685,984?
It can potentially fall within the claims covering PSI-7977 and GS-5885 if the patient is treatment-naive, has genotype 1 infection, receives no interferon or ribavirin, and receives the regimen for eight weeks.
Does the patent cover sofosbuvir alone?
No. The supplied claims require sofosbuvir, identified as PSI-7977, together with GS-5885, identified as ledipasvir. They do not claim sofosbuvir monotherapy.
Does the patent cover a 12-week Viekira Pak regimen?
Potentially, if the regimen satisfies the named compound, ritonavir, dose, patient, and administration limitations. The 12-week duration appears in claim 12 and its dependent claims, but every other limitation must also be met.
Can a generic applicant avoid the patent by omitting the eight-week indication?
Possibly. A section viii strategy may avoid a patented method-of-use claim if the proposed label excludes the protected use and the remaining label does not induce infringement.
Is US Patent 8,685,984 a patent on Harvoni itself?
No. It is a method patent directed to treatment using the sofosbuvir and ledipasvir combination. Separate patents may cover the active ingredients, formulations, crystalline forms, manufacturing processes, or other methods of use.
References
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,685,984, methods for treating hepatitis C virus infection.
- U.S. Food and Drug Administration. (2014). FDA approves Viekira Pak to treat hepatitis C.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Gilead Sciences, Inc. (2015). Annual report for fiscal year 2014.
- AbbVie Inc. (2015). Annual report for fiscal year 2014.
